Mercado global de tratamento da adenomiose – Tendências do setor e previsão para 2028

Análise de mercado e insights: Mercado global de tratamento da adenomiose

Prevê-se que o mercado de tratamento da adenomiose ganhe crescimento de mercado no período de previsão de 2021 a 2028. A Data Bridge Market Research analisa que o mercado está a crescer a um CAGR robusto de 5,10% no período de previsão de investigação acima mencionado. O aumento dos recursos provenientes da investigação e desenvolvimento, o aumento da ocorrência de adenomiose, a sensibilização e o conhecimento sobre o advento da doença de novos medicamentos, tecnologia médica e terapias são os fatores responsáveis ​​pelo crescimento do mercado de tratamento da adenomiose.

A adenomiose é a existência de glândulas endometriais ectópicas e estroma que é rodeado por músculo liso hiperplásico no miométrio. É uma doença uterina associada a dor pélvica, hemorragia uterina anormal (AUB) e infertilidade. As duas formas patológicas diferentes são difusas e locais. O tratamento da adenomiose depende da proximidade do doente com o estádio da adenomiose. A adenomiose cessa geralmente após a menopausa. As opções de tratamento são os anti-inflamatórios, como o ibuprofeno, medicamentos hormonais, como os adesivos contendo hormonas, que reduzem as hemorragias excessivas e a dor associada à adenomiose. A histerectomia é aplicada quando a dor é intensa e o ginecologista pode sugerir a remoção do útero.

The latest technological advancement for treatment of adenomyosis is the levonorgestrel-releasing intrauterine system (LNG-IUS). It’s an effective, reversible and long-term potential treatment used successfully to treat adenomyosis. The treatment curbs menstrual bleeding, pain and uterine volume and has an overall satisfaction of 72%. New drugs such as selective progesterone receptor modulators, aromatase inhibitors, valproic acid and anti-platelet therapy are under development for the treatment of adenomyosis. The rise in prevalence of adenomyosis is the major factor driving the adenomyosis treatment market growth. A prevalence of 20% to 35% of women who suffered adenomyosis has been reported. Rise in funds from research and development (R&D) and government, rise in occurrence of adenomyosis, awareness and knowledge about the disease advent of new drugs, medical technology and therapies are the factors responsible for the growth of the adenomyosis treatment market. However, certain challenges faced are increased cost, lack of certain medical infrastructure and treatment to cure adenomyosis will tamper the adenomyosis treatment market growth.

This adenomyosis treatment market provides details of market share, new developments and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions and technological innovations in the market. To understand the analysis and the adenomyosis treatment market scenario contact Data Bridge Market Research for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Adenomyosis Treatment Market Scope and Market Size

The adenomyosis treatment market is segmented on the basis of type, diagnosis and treatment. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

• On the basis of type, the adenomyosis treatment market is segmented into focal, adenomyoma, diffuse and others.
• On the basis of diagnosis, the adenomyosis treatment market is bifurcated into endometrial biopsy, ultrasound, magnetic resonance imaging (MRI) and others. Ultrasound is sub-segmented into transabdominal and transvaginal/endovaginal.
• On the basis of treatment, the adenomyosis treatment market has also been segmented into anti-inflammatory drugs, hormone medications, hysterectomy and others. Anti-inflammatory drugs are sub-segmented into ibuprofen, motrin IB, advil and others. Hormone medications are sub-segmented into gonadotropin-releasing hormone (GnRH) agonists, aromatase inhibitors and others. Hysterectomy is sub-segmented into supracervial or subtotal hysterectomy, total hysterectomy and radical hysterectomy.

Global Adenomyosis Treatment Market Country Level Analysis

Global adenomyosis treatment market is analysed and market size information is provided by country, type, diagnosis and treatment as referenced above.

The countries covered in the global adenomyosis treatment market report are the U.S., Canada, Mexico in North America, Brazil, Argentina, Peru, Rest of South America, as part of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa, as a part of Middle East and Africa.

On geographical estimation, the U.S. in North America is expected to hold the largest market share followed by Europe. The growth frequency in Western European countries is higher. The Asia-Pacific is anticipated to become the fastest growing market in the estimate period due to the factors such as rise in knowledge about the disease and treatments, upcoming healthcare infrastructure and increased disbursement on healthcare. However, Middle East and Africa (MEA) are probably to have a less growth in market revenue due to minimum cognizance about the medical devices and treatment.

The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Patient Epidemiology Analysis : Global Adenomyosis Treatment Market

O mercado global de tratamento da adenomiose também fornece análises de mercado detalhadas para análise de pacientes, prognóstico e curas. Prevalência, incidência, mortalidade, taxas de adesão são algumas das variáveis ​​de dados disponíveis no relatório. A análise de impacto direto ou indireto da epidemiologia no crescimento do mercado de tratamento da adenomiose é analisada para criar um modelo estatístico multivariado mais robusto e de coorte para prever o mercado de tratamento da adenomiose no período de crescimento.

Cenário competitivo e análise global da quota de mercado do tratamento da adenomiose

O panorama competitivo do mercado global de tratamento da adenomiose fornece detalhes por concorrente. Os detalhes incluídos são a visão geral da empresa, finanças da empresa, receitas geradas, potencial de mercado, investimento em investigação e desenvolvimento, novas iniciativas de mercado, presença global, localizações e instalações de produção, pontos fortes e fracos da empresa, lançamento de produtos , pipelines de ensaios clínicos, aprovações de produtos, patentes, largura e amplitude do produto, domínio da aplicação, curva de segurança da tecnologia. Os dados acima fornecidos estão apenas relacionados com o foco das empresas relacionado com o mercado global de tratamento da adenomiose.

Os principais players abrangidos no mercado global de tratamento da adenomiose são a Bayer AG, Ferring BV, Johnson & Johnson Services, Inc., Novartis AG, Merck KGaA, Pfizer Inc., Specialty European Pharma, entre outros players nacionais e globais. Os analistas DBMR compreendem os pontos fortes competitivos e fornecem análises competitivas para cada concorrente em separado.

Os principais intervenientes patrocinaram os ensaios clínicos de determinados medicamentos para o tratamento da adenomiose. O dienogest (visanne) da Bayer AG está em ensaio clínico de Fase III.

SKU-58753